Clinical Trial Update: A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating KAE609 (cipargamin) for Plasmodium falciparum malaria in adult males has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• KAE609 (cipargamin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Malaria | Phase 2 | Status: COMPLETED | Results posted: 2016-10-31